Article Versions Notes

Mussa A, Carli D, Giorgio E, Villar AM, Cardaropoli S, Carbonara C, Campagnoli MF, Galletto P, Palumbo M, Olivieri S, et al. MEK Inhibition in a Newborn with RAF1-Associated Noonan Syndrome Ameliorates Hypertrophic Cardiomyopathy but Is Insufficient to Revert Pulmonary Vascular Disease. Genes. 2022; 13(1):6. https://doi.org/10.3390/genes13010006

Mussa, Alessandro, Diana Carli, Elisa Giorgio, Anna Maria Villar, Simona Cardaropoli, Caterina Carbonara, Maria Francesca Campagnoli, Paolo Galletto, Martina Palumbo, Simone Olivieri, and et al. 2022. "MEK Inhibition in a Newborn with RAF1-Associated Noonan Syndrome Ameliorates Hypertrophic Cardiomyopathy but Is Insufficient to Revert Pulmonary Vascular Disease" Genes 13, no. 1: 6. https://doi.org/10.3390/genes13010006

Mussa, A., Carli, D., Giorgio, E., Villar, A. M., Cardaropoli, S., Carbonara, C., Campagnoli, M. F., Galletto, P., Palumbo, M., Olivieri, S., Isella, C., Andelfinger, G., Tartaglia, M., Botta, G., Brusco, A., Medico, E., & Ferrero, G. B. (2022). MEK Inhibition in a Newborn with RAF1-Associated Noonan Syndrome Ameliorates Hypertrophic Cardiomyopathy but Is Insufficient to Revert Pulmonary Vascular Disease. Genes, 13(1), 6. https://doi.org/10.3390/genes13010006